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Extract of NIH3T3 mouse fibroblasts contains a protease which can cleave epidermal growth factor receptor (EGF recep- 
tor). This protease was tentatively named cathepsin X and purified to near homogeneity. The characteristics of cathepsin 
X were similar to those ofcathepsin L and the proteolytic activity of cathepsin X was inhibited by c-Ha-ras gene products. 
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1. INTRODUCTION 
During the course of investigation on CAMP- 
dependent protein kinases [1,2], we have found 
that c-Ha-ras gene products (~21s) produced by 
Escherichia coli have cysteine proteinase-inhibitor 
activity [3,4]. Although ~21s have been found to 
suppress the proteolytic degradation of a CAMP- 
binding protein [3], it is possible that ~21s can in- 
hibit the degradation of other proteins which are 
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more closely related to cell growth. First of all, the 
degradation of EGF receptor was investigated by 
purifying a protease which can cleave EGF recep- 
tor followed by examining whether the proteolytic 
activity of the protease can be inhibited by ~21s. 
2. MATERIALS AND METHODS 
2.1. Preparation of ~21s and cathepsin L
~21s were produced in Escherichia coli with plasmids bearing 
human c-Ha-ras genes and purified as described previously 
[3-51. p2l(G,l71) andp2l(V,171) are truncated ~21s of ‘Met to 
“‘Leu and have glycine and valine, respectively, at position 12. 
Cathepsin L was purified from rat kidney according to [6]. 
2.2. Immunoprecipitation of EGF-receptor 
A431 cells grown on a lOO-mm dish were labeled with 
[%]methionine and [‘%]cysteine for 16 h at a concentration of 
0.2 mCi/ml. Cell extract was prepared with buffer A (O.SOro 
Nonidet P-40, 10 mM Tris-HCI, pH 7.4, 10 mM NaCl, 3 mM 
MgC12, 1 mM dithiothreitol (DTT) and 1 mM phenylmeth- 
ylsulfonyl fluoride (PMSF)) as described [7] and incubated at 
37°C for 30 min with an appropriate amount of the protease 
fraction. EGF receptors were immunoprecipitated with anti- 
EGF receptor monoclonal antibody (Transformation Research 
Inc., Framingham, MA) as described previously [8]. The 
solubilized materials were analyzed by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) [9]. 
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2.3. Pur@ation of cathepsin X 12345678910 
Cathepsin X was purified from NIH3T3 mouse fibroblasts as 
follows. Approximately 1 x lo9 cells were harvested and wash- 
ed 4 times with phosphate-buffered saline. The cell pellet was 
mixed with 15 ml of buffer A, incubated at 0°C for 10 mitt, and 
centrifuged at 10000 x g for 10 min. The supernatant was 
dialyzed against buffer B (20 mM sodium acetate, pH 5.0, 
50 mM NaCI, 1 mM EDTA and 5 mM P-mercaptoethanol) and 
applied to a column (2.5 cm x 30 cm) of CM-Sephadex C-50 
pre-equilibrated in the same buffer. After washing with buffer 
B, the column was eluted with a linear gradient (0.05 to 0.5 M) 
of NaCl in buffer B. Cathepsin X was eluted at 0.1 to 0.3 M 
NaCl concentration. The active fractions were concentrated 
with ultrafiltration (Amicon, PMlO), dialyzed against buffer C 
(20 mM sodium phosphate buffer, pH 6.0, 1 mM EDTA and 
1.4 mM ,&mercaptoethanol), and applied to a column 
(1.5 cm x 15 cm) of DEAE-cellulose (DE52, Whatman) pre- 
equilibrated in buffer C. After washing with buffer C, the col- 
umn was eluted with a linear gradient (O-O.4 M) of NaCl in 
buffer C (2 x 100 ml). Cathepsin X was eluted at approx. 
0.05 M NaCI. The active fractions were directly applied to a 
column (1.2 cm x 8 cm) of hydroxyapatite (Nakarai Chemicals 
Co. Ltd, Osaka, Japan). After washing with buffer C, the col- 
umn was eluted with a linear gradient (20-500 mM) of sodium 
phosphate buffer (pH 6.0) in the presence of 1 mM EDTA and 
1.4 mM P-mercaptoethanol. Cathepsin X was eluted at a 
phosphate concentration of approx. 350 mM. The active frac- 
tions were combined, concentrated with ultrafiltration, dialyzed 
against buffer C, and further purified with AcA44 (LKB) gel 
filtration. The activity of cathepsin X to cleave the 150-kDa 
EGF-receptor was investigated by treatment of A431 cell extract 
with cathepsin X followed by immunoprecipitation of EGF 





Fig.1. Cleavage of EGF-receptor by cathepsin X. A431 cell 
extracts were incubated at 30°C for 30 min (lanes 2-10) in the 
presence of 1 mU cathepsin X (lanes 3-10) and various 
inhibitors (lanes 4-10). The inhibitors and their concentrations 
were as follows: lane 4, E-64, 10 pM; lane 5, antipain, 10 pM; 
lane 6, leupeptin, 10 pM; lane 7, TLCK, 10 PM; lane 8, TPCK, 
IOpM; lane 9, p21(G,171), SOpg/ml; lane 10, p21(V,171), 
50 @g/ml. The extract without incubation is shown in lane 1. 
Other conditions of incubation and immunoprecipitation were 
carried out. The positions of molecular mass markers and two 
types of EGF receptors are shown on the left and right, 
respectively. 
2.4. Immunoblot analysis 
Immunoblot analysis was carried out according to [lo]. 
Cathepsin X and rat cathepsin L were subjected to SDS-PAGE 
(11% acrylamide), transferred to a nitrocellulose filter, and 
probed with rabbit anti-rat cathepsin L antibody [6]. The filter 
was incubated with goat anti-rabbit IgG antibody coupled with 
horseradish peroxidase and then incubated with the 
4-chloro-1-naphthol substrate. 
2.5. Assay for the proteolytic activity of cathepsin X 
The activity of cathepsin X to cleave the synthetic substrate, 
benzyloxycarbonyl-phenylalanyl-arginine 4-methyl-7-couma- 
rylamide (Z-Phe-Arg-NMec) was measured in the absence or 
presence of p21(G,171) or p21(V,l71) as described [3,4,11]. The 
activities of each protease were adjusted to 0.2 mU (one unit of 
enzyme activity is defined as the amount of enzyme necessary 
to release 1 pmol of 7-amino-4-methylcoumarin per min at 
37°C) and the incubation was carried out at 37°C for 10 min. 
extracts with anti-EGF receptor antibody (fig. 1, 
lane 1). NIH3T3 mouse fibroblasts contain high 
activity to cleave the 150-kDa EGF receptor at 
acidic conditions. This EGF receptor-cleaving pro- 
teinase was tentatively named ‘cathepsin X’, which 
binds CM-Sephadex and is eluted with 0.1 to 
0.2 M NaCl (not shown). The elution profile of 
cathepsin X from CM-Sephadex was similar to 
that of rat cathepsin L [6]. Cathepsin X was fur- 
ther purified by the methods of DEAE-cellulose 
and hydroxyapatite column chromatography and 
AcA44 gel filtration. 
3. RESULTS 
Human epidermoid carcinoma A431 cells 
overexpress EGF receptor [12,13]. A typical 
170-kDa/150-kDa doublet of EGF receptors was 
observed after immunoprecipitation of A431 cell 
The purity of the AcA44-purified cathepsin X 
was higher than 95% and the molecular mass of 
the major band was 31 kDa (fig.2a) which is 
similar to that of the single-chain form of cathep- 
sin L [6]. Anti-rat cathepsin L antibody reacted 
with the 31-kDa cathepsin X as well as cathepsin L, 
which showed the 25kDa heavy-chain form 
(fig.2b). 
The 150-kDa EGF receptor was selectively 
cleaved by cathepsin X and the cleavage was in- 








Fig.2. SDS-PAGE and immunoblot analysis of purified 
cathepsin X. (a) SDS-PAGE of cathepsin X. Cathepsin X 
purified from NIH3T3 cells was resolved by SDS-PAGE (10% 
acrylamide), and stained with silver (Silver Staining Reagent, 
Daiichi Chemicals, Japan). (b) Immunoblot analysis of purified 
cathepsin X. Cathepsin X and rat cathepsin L were resolved by 
SDS-PAGE (11% polyacrylamide), transferred to a 
nitrocellulose filter, and analyzed by immunoblotting for 
reactivity with anti-rat cathepsin L antiserum. 
boxyoxiran-2-carbonyl)-L-leucyllagmatine (E-64) 
1141, antipain, leupeptin and p-tosyl-L-lysine 
chloromethylketone (TLCK) (fig. 1). p-tosyl-l- 
phenylalanine chloromethylketone (TPCK) in- 
hibited it partially. 
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Z-Phe-Arg-NMec which is a common substrate 
for cathepsins B and L [l l] was also cleaved by 
cathepsin X. The cleavage of Z-Phe-Arg-NMec by 
cathepsin X was inhibited by ~21s dose- 
dependently (fig.3). The inhibition profile of 
cathepsin X by ~21s was comparable to that of 
cathepsin L. Cathepsin X failed to cleave Z-Arg- 
Arg-NMec (not shown). These results suggest that 
cathepsin X is quite similar to cathepsin L. 
4. DISCUSSION 
Many characteristics of cathepsin X were similar 
to those of rat cathepsin L; e.g., elution profiles 
from CM-Sephadex and DEAE-cellulose, a 
molecular mass of 31 kDa, reaction with anti-rat 
cathepsin L, cleavage of Z-Phe-Arg-NMec, and in- 
hibition by various protease inhibitors including 
~21s. Therefore, cathepsin X may be cathepsin L 
itself or other cathepsin L-related protease such as 
cathepsin S [15]. 
Cathepsin X is the major protease which can 
cleave EGF-receptor and ~21s can inhibit cathep- 
sin X-induced degradation of EGF receptor. 
Taken together, it is possible that ~21s can protect 
EGF receptor against the specific protease. 
Although the exact situation of the contact among 
EGF receptor, p21 and cathepsin X has not been 
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Fig.3. Inhibition of the activity of cathepsin X by ~21s. The activities of cathepsins X and L were measured in the presence of varying 
amounts of ~21s. The protease activity in the absence of ~21s is expressed as 100%. Each point represents the average value of two 
assays. (0) p21(G,l71); (A) p21(V,171). 
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example, at the time of receptor-mediated en- 
docytosis. After EGF receptor binds to EGF, it is 
rapidly endocytosed and subsequently degraded by 
lysosomal proteases [ 16,171. If the degradation of 
the internalized EGF receptor is inhibited by ~21s 
in vivo, the stabilized receptor may stimulate cell 
growth constitutively. 
Finally, it is probable that cathepsin L-like pro- 
tease may be involved in the degradation of other 
kinds of growth factor receptors and that ~21s can 
generally suppress the down-regulation of many 
kinds of receptors. 
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